Innovative Vaccine Trial for Canines with Early Stage Hemangiosarcoma

Wednesday, 2 October 2024, 13:50

Calviri's novel vaccine trial for canines aims to improve outcomes for dogs diagnosed with early stage hemangiosarcoma. This investigational therapy may enhance survival rates for canine patients. The trial, named Scout Out Canine Hemangiosarcoma (SOCH), evaluates a pre-made vaccine's efficacy alongside standard treatment.
Dvm360
Innovative Vaccine Trial for Canines with Early Stage Hemangiosarcoma

Calviri has initiated a groundbreaking vaccine trial for canines diagnosed with early stage hemangiosarcoma (HSA). The trial, known as the Scout Out Canine Hemangiosarcoma (SOCH), focuses on whether Calviri's investigational immunotherapy vaccine can extend the lifespan of dogs with stage 1 or stage 2 tumors when combined with conventional treatments such as surgery and chemotherapy.

The primary aim of this vaccine is to stimulate the immune system to recognize and destroy cancer cells. Utilizing neoantigens derived from tumor RNA variants, Calviri is positioned to offer off-the-shelf solutions for treating canine tumors. Unlike most cancer vaccines that target advanced stages, the SOCH trial represents a significant step towards addressing early-stage tumors, giving hope for better survival rates.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe